Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A₁chieve study.

Bebakar WM, Lim-Abrahan MA, Jain AB, Seah D, Soewondo P.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S17-23. doi: 10.1016/S0168-8227(13)70005-6.

PMID:
23647713
2.

Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.

Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S24-9. doi: 10.1016/S0168-8227(13)70006-8.

PMID:
23647714
3.

Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

Lim-Abrahan MA, Jain AB, Bebakar WM, Seah D, Soewondo P.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S3-9. doi: 10.1016/S0168-8227(13)70003-2.

PMID:
23647715
4.

Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.

Latif ZA, Pathan MF, Siddiqui MN, Sobhan MJ, Rahman MM, Ashrafuzzaman SM.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S30-4. doi: 10.1016/S0168-8227(13)70007-X.

PMID:
23647716
5.

Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.

Belhadj M, Dahaoui A, Jamoussi H, Farouqi A.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S4-14. doi: 10.1016/S0168-8227(13)70014-7.

PMID:
23958571
6.

Safety and effectiveness of insulin detemir in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.

Soewondo P, Mohamed M, Jain AB, Sy RA, Khoo CM.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S10-6. doi: 10.1016/S0168-8227(13)70004-4.

PMID:
23647712
7.

Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.

Soewondo P, Lindarto D, Wibisono S, Renaldi O, Dalem-Pemayun TG.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S41-6. doi: 10.1016/S0168-8227(13)70009-3.

PMID:
23647718
8.

Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.

Malek R, Arbouche Z, Dahaoui A, Bachaoui M.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S15-26. doi: 10.1016/S0168-8227(13)70015-9.

PMID:
23958568
9.

Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.

Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S35-40. doi: 10.1016/S0168-8227(13)70008-1.

PMID:
23647717
10.

Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.

Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S54-9. doi: 10.1016/S0168-8227(13)70011-1.

PMID:
23647720
11.

Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.

Chraibi A, Ajdi F, Belkhadir J, El Ansari N, Marouan F, Farouqi A.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S27-36. doi: 10.1016/S0168-8227(13)70016-0.

PMID:
23958569
12.

Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.

Soewondo P, Kshanti IA, Pramono RB, Langi YA, Dalem-Pemayun TG.

Diabetes Res Clin Pract. 2013 Apr;100 Suppl 1:S47-53. doi: 10.1016/S0168-8227(13)70010-X.

PMID:
23647719
14.

Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.

Lezzar A, Ayad F, Dahaoui A, Salah-Mansour A, Berrouiguet AY.

Diabetes Res Clin Pract. 2013 Aug;101 Suppl 1:S37-44. doi: 10.1016/S0168-8227(13)70017-2.

PMID:
23958570
15.

Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.

El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J.

Diabetes Res Clin Pract. 2012 Dec;98(3):408-13. doi: 10.1016/j.diabres.2012.09.043.

PMID:
23217267
16.

Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.

Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.

Prim Care Diabetes. 2014 Jul;8(2):111-7. doi: 10.1016/j.pcd.2013.07.005. Epub 2013 Aug 14.

PMID:
23953707
17.

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.

Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS; BOOST: Intensify All Trial Investigators.

Diabetes Res Clin Pract. 2015 Jan;107(1):139-47. doi: 10.1016/j.diabres.2014.09.026. Epub 2014 Oct 14.

18.

Biphasic insulin aspart 30 improved glycemic control in Chinese patients with type 2 diabetes poorly controlled on oral glucose-lowering drugs: a subgroup analysis of the A₁chieve study.

Chen L, Xing X, Lei M, Liu J, Shi Y, Li P, Qin G, Li C, Li Y, Wang Q, Gao T, Hu L, Wang Y, Yang W.

Chin Med J (Engl). 2014;127(2):208-12.

20.

Safety and efficacy of insulin aspart and soluble human insulin in Type 2 diabetes mellitus.

Cucinotta D, Caputo S, Mannucci E, Nicolucci A, Pellegrini F, Perriello G, Sbraccia P.

Minerva Endocrinol. 2012 Dec;37(4):357-66.

PMID:
23235191
Items per page

Supplemental Content

Write to the Help Desk